Purpose: To analyze macular pigment (MP) amount and distribution in patients with macular telangiectasia Type 2 receiving oral zeaxanthin supplementation in a randomized, open-label, interventional trial.
M acular telangiectasia Type 2 (MacTel) is a rare disease entity initially characterized and classified by Gass and Blodi 1 based on histologic, slit-lamp biomicroscopic, and fluorescein angiographic findings. The staging classification was further refined by Yannuzzi et al. 2 Patients with MacTel typically present with progressive decrease in vision in the fifth to seventh decades of life. 1, 3 The clinical findings include telangiectatic retinal vessels, loss of retinal transparency with parafoveal graying, telangiectatic retinal vessels, intraretinal crystalline deposits, right-angled vessels, foveal atrophy, hyperplasia of the retinal pigment epithelium, and retinal neovascularization. 1, [3] [4] [5] Despite extensive clinical characterization, the underlying genetic and physiologic origins of MacTel have not yet been elucidated, but redistribution of the macular carotenoid pigments into a ring-shaped pattern is one of the earliest signs of the disorder. [6] [7] [8] Carotenoids are ubiquitous pigments synthesized exclusively by plants and microorganisms. There are more than 15 different dietary carotenoids detectable in human serum; however, only lutein, zeaxanthin, and meso-zeaxanthin are found in the retina, typically in a peaked distribution centered at the fovea. [9] [10] [11] [12] Collectively, these are known as the macular pigment (MP). Previous studies have characterized unique changes in MP distribution using autofluorescence images and confocal blue reflectance in patients with MacTel. [13] [14] [15] Zeimer et al 6 further classified a continuum of changes in MP using two-wavelength autofluorescence imaging (AFI). The most advanced class (Class III) described by their study was characterized by an oval effacement of MP in the center of the fovea and a surrounding ring of MP at 5°to 7°eccentricity. Supplementation with lutein and zeaxanthin has been shown to enhance central MP optical density (MPOD) in patients with age-related macular degeneration 16 ; however, high-dose lutein and low-dose zeaxanthin supplementation failed to increase MP levels lost in the central fovea of Class III MacTel patients. 7 A comprehensive battery of in vitro and in vivo studies using high dosage of zeaxanthin revealed no evidence for mutagenicity or target-organ toxicity. 17 Human intervention studies indicate good systemic tolerance of zeaxanthin. Van de Kraats et al 18 showed no systemic toxicity with a dose of up to 20 mg/day for up to 6 months.
We sought to determine if high-dose zeaxanthin supplementation would be more successful in MacTel patients given that its distribution peaks more sharply at the fovea in normal eyes relative to lutein. 19, 20 Our main aim was to determine the amount and distribution of MP in MacTel patients receiving oral zeaxanthin. Our next aim was to determine if high-dose zeaxanthin supplementation could preserve or enhance visual function as measured by visual acuity and contrast sensitivity (CS). Finally, we report a novel, reversible, crystalline maculopathy in response to zeaxanthin supplementation that was reminiscent of canthaxanthin crystalline maculopathy.
Methods

Subjects
The study was conducted under clinical trials number NCT01354093 and IND112316 as part of the MacTel Project (www.mactelresearch.org), which is the first longitudinal, international, multicenter trial to investigate the natural history of MacTel in a large patient cohort.
Eight patients with MacTel were recruited for this investigation. They had no history of lutein or zeaxanthin supplementation. The study was approved by the local medical ethics committee and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all patients before the study.
Inclusion criteria for this investigation were as follows: either gender who have MacTel (as confirmed by the MacTel Central Study Reading Centre in London), age older than 18 years, ability to travel to the University of Utah for all study evaluations, and no history of lutein or zeaxanthin supplementation.
The 8 study subjects were aged between 38 and 79 years. The male to female ratio was 1:7. Best-corrected distance visual acuities were tested at 4 m with standard Early Treatment Diabetic Retinopathy Study protocols and converted to Snellen equivalents. These values were then transformed to logarithm of the minimum angle of resolution values for statistical analysis. Contrast sensitivity was tested with the CSV-1000 (Vector Vision, Dayton, OH) contrast sensitivity testing instrument. A CS curve comprised 4 rows (A, B, C, and D) plotted for each patient, specifically testing 3, 6, 12, and 18 cycles per degree, respectively.
At each visit, all patients were dilated using 0.5% tropicamide and 2.5% phenylephrine. Afterward, slitlamp biomicroscopy, color fundus photography, optical coherence tomography (OCT), and single-wavelength AFI with the Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, Germany) were performed. Blood was also drawn to assess serum zeaxanthin levels.
Classification of MP distribution was carried out by a single investigator (P.S.B.) from fundus autofluorescence images. All eight patients were graded as Class III, as per the classification scheme proposed by Zeimer et al. 6 The patients were randomly assigned to receive 20 mg or 10 mg of zeaxanthin a day (EyePromise Zeaxanthin; ZeaVision, LLC, St Louis, MO). Every 6 months, serum levels of zeaxanthin, visual acuity, CS, fundus biomicroscopy, OCT, and MP concentration by autofluorescence were analyzed. After 24 months, supplementation was stopped at the conclusion of the study. were exported into and processed with ImageJ software (NIH, Bethesda, MD). As described in detail in the study by Sharifzadeh et al, 21 individual image pixels were first grouped into small, discrete, circular pixel areas, with each "disk" containing 30 pixels, and each disk chosen at strategic AFI image regions lying on the MP ring and outside the ring, respectively. For each disk, the individual autofluorescence pixel intensities, I, were averaged, resulting in a corresponding average local disk intensity value, I ave . Next, a disk on the ring was identified that had the lowest autofluorescence intensity, I min(ave) , resulting from the highest carotenoid absorption for the excitation light. In a third step, 10 "reference" disks with highest autofluorescence intensities, I max , were selected at eccentricities greater than 7°, image locations where carotenoid absorptions are virtually absent. Areas with blood vessels or other retinal abnormalities, such as retinal holes, hemorrhaging, retinal pigment epithelial atrophy, or retinal pigment epithelial hypertrophy, were excluded in the selection of the reference disks.
The maximum obtainable image contrast is calculated as the ratio between the averaged high autofluorescence intensities of the 10 reference disks, I max (ave) , and the lowest autofluorescence intensities of the disk on the ring, I min(ave) . This ratio, I max(ave) /I min(ave) , is proportional to the MPOD according to the following relation. 21 MPOD ¼ 1:4 · log I maxðaveÞ I minðaveÞ ! ; where 1.4 is a calibration factor, taking into account the spectral mismatch between the MP absorption band maximum at 460 nm 22 and the excitation wavelength at 488 nm. Images and data from only one eye from each patient were used for analysis at all time points as determined by a masked reviewer based on the eye with the best quality set of autofluorescence images.
Serum Carotenoid Assessment
Standards of lutein, zeaxanthin, a-carotene, b-carotene, lycopene, 39-oxolutein, and b-cryptoxanthin were from Kemin Health (Des Moines, IA), DSM (Kaiseraugst, Switzerland), and Dr. Fred Khachik (University of Maryland, Baltimore, MD). Organic solvents were high-performance liquid chromatography grade from Fisher Scientific (Hampton, NH). Serum (0.2 mL) was extracted using ethanol containing 0.1% butylated hydroxytolutene: ethyl acetate (4:10), followed by hexane extraction. The organic extracts were evaporated to dryness by flushing with inert gas, and the residues were reconstituted in methanol:methyl tert-butyl ether (80:20 vol/vol) and centrifuged at 2,000g before analysis.
Separation of carotenoids was carried out on a Surveyor Plus HPLC system (Thermo Scientific, Waltham, MA) equipped with an autosampler and photodiode array detector, on a C30 column (YMC Europe GmbH, Dinslaken, Germany) (250 · 4.6 mm inner diameter) at a flow rate of 1.0 mL/minute. 23 A linear gradient of methanol and methyl tert-butyl ether (%methanol @ min: 95 @ 0; 70 @ 20; 40 @ 30; 5 @ 40; 95 @ 45; 95 @ 50) was used as mobile phase, and the column was maintained at room temperature with the photodiode array detector operated at 450 nm. Peaks were identified and confirmed using photodiode array spectra and by coelution with authentic standards as necessary. Standard solutions of each individual carotenoid with known concentrations were calculated spectrophotometrically using published extinction coefficients 24, 25 and were injected in different volumes so as to achieve final injected amounts ranging from 0.1 ng to 100 ng. The carotenoid content was quantitated using standard curves of available standards.
Results
Serum Zeaxanthin Levels: Response to Supplementation
All patients were compliant with oral zeaxanthin supplementation as assessed by .98% compliance by pill counts. Supplementation resulted in an increase in serum zeaxanthin levels from baseline in all patients but with wide variability. The initial levels of increase and time-dependent profiles of serum zeaxanthin levels for the next 24 months are shown for all the patients (Figure 1) . Patient D was taken off of supplementation at 6 months because of the formation of retinal crystals, which explains the sharp decrease in zeaxanthin levels at 8 months (Figure 1 ). The patient was restarted on 10 mg/day of zeaxanthin supplementation at 10 months once the retinal crystals disappeared, and she had a subsequent increase in serum zeaxanthin levels measured at 12 months. Of note, patients did not have any dietary restrictions throughout the study, and there was a common trend for serum zeaxanthin levels to peak at 6 months to 12 months, followed by declining serum zeaxanthin levels at the later time points.
Classification of Macular Pigment Optical Density in Patients With Idiopathic Macular Telangiectasia
As established by Zeimer et al, 6 the classification system for patterns of MP distribution was used to categorize each patient. At baseline and study completion, all patients were noted to be Class III, which corresponds to an oval effacement of MP centrally with a surrounding halo of MP at 5°to 7°eccentricity ( Figure 2 ).
Macular Pigment Optical Density Response to Supplemental Zeaxanthin
All patients had an initial increase in the maximum MPOD level with zeaxanthin supplementation (Figure 3 ). Although all patients showed an increase in MPOD levels, this augmentation was solely in the oval-shaped perifoveal halo of MP in 5°to 7°eccentricity (Figure 2 There was no discernable correlation between visual acuity, OCT thickness, and CS with MPOD (n = 8; Table 1 ). There was a general decrease in visual acuity and CS with time. No trend could be established with macular thickness as measured by OCT.
Retinal Crystal Formation While on Zeaxanthin Supplementation
One patient (Patient D) developed yellowish retinal crystals in her macula while on oral zeaxanthin supplementation. They were first discovered with fundoscopic examination at 6 months after starting 20 mg/day of oral zeaxanthin supplementation, and AFI confirmed that they had no intrinsic fluorescence and that they blocked underlying choroidal autofluorescence, consistent with the optical properties of the macular carotenoid pigments ( Figure 4B ). Images of OCT indicated that these crystals were in the inner retina ( Figure 5 ), which differentiates these crystals from those typically seen in MacTel patients at the vitreoretinal interface, which are neither hypofluorescent nor hyperfluorescent. Upon observing these crystals, the patient was taken off of zeaxanthin supplementation. As Figure 3 ). The retinal crystals were no longer detectable at this time ( Figure 4C ), suggesting that these crystals were a direct result of oral zeaxanthin supplementation.
Discussion
Lutein, zeaxanthin, and meso-zeaxanthin are the three carotenoids that accumulate at the macula and are defined as MP. 16, [26] [27] [28] Their redistribution appears to be a novel phenotypic characteristic specific to MacTel. 6, 7, 14, 15 Because of this unique feature, it is hypothesized that MP pattern changes may be important pathophysiological features of this disease. The MP is thought to offer protection against retinal damage via its short-wavelength light screening and antioxidant properties. 9, 29 Extensive knowledge regarding the molecular and storage mechanisms for MPs is lacking; however, the high concentrations of MP in the retina compared with the blood indicate active transport and concentration mechanisms. Additionally, past studies have indicated that specialized carotenoidbinding proteins and relative inactivity of carotenoidspecific cleavage enzymes in humans are involved in selective uptake and deposition in the macula. [30] [31] [32] There is conflicting evidence in the literature about whether a relationship exists between MPOD levels and zeaxanthin dietary supplementation. Some studies suggest the absence of a clear relationship between carotenoid dietary supplementation or plasma carotenoid levels and MPOD levels. 33, 34 In other studies, lutein and zeaxanthin supplementation has been shown to increase MPOD in patients with age-related macular degeneration. [35] [36] [37] A subsequent study determined that over a 9-month period, supplementation with a high concentration of lutein could increase MPOD in patients with MacTel; however, this occurred only in areas where MP accumulation was still present at baseline. 7 Naturally, we asked if supplementation with high doses of zeaxanthin could normalize MP distribution in patients with MacTel, given that its distribution peaks more sharply at the fovea than lutein in normal eyes. 19, 20 Furthermore, one study determined that zeaxanthin was more reduced compared with lutein in the macula of patients with MacTel. 14 In an earlier pilot study, a continuum of changes in the distribution of MP was observed in patients with MacTel, and a classification system was developed. 6 At baseline, all patients in our study met criteria for Class III, which is characterized by an oval effacement of MP in the center of the fovea and a surrounding ring of MP at 5°to 7°. After supplementation with high-dose zeaxanthin, MPOD levels increased at an eccentricity of 5°t o 7°only, with no increase detected between 0.5°and 2°eccentricity, where MP was not present at baseline.
The exact mechanisms governing MP redistribution in MacTel have still not been elucidated. Previous studies suggested that it may be the result of progressive anatomic changes in the central retina. 6 Histologic analyses have shown that MP is mainly localized in the outer plexiform layer. It is possible that the axons of photoreceptors and Muller glial cells may be structurally altered in MacTel, and prior reports provide evidence of Muller cell loss specifically in areas of depleted MP. 38, 39 Furthermore, Degli Esposti et al 40 determined that the mean total amount of MP within the central 21°was greater for normal subjects than for patients with an annular distribution of MP, suggesting that there is a cumulative loss of MP in MacTel.
The visual acuity and CS values progressively worsened for all patients regardless of the elevation of MP levels at 5°to 7°eccentricity. Robust statistical analyses could not be performed for these functional measurements of vision because of the small cohort of patients. Despite this limitation, we can conclude that increases in MP at 5°to 7°eccentricity did not result in any functional improvement in vision as measured by visual acuity and CS in our cohort. Of note, there was no difference in OCT thickness between the beginning and end of the study.
Serum zeaxanthin levels initially increased in all patients when started on supplementation. Over time, each patient had varying levels that tended to peak at approximately 12 months. This may be because each subject's individual phenotype for various carotenoidspecific regulatory, binding, and transport proteins vary as has been described in the literature. 30, [41] [42] [43] [44] [45] [46] [47] The lack of obvious correlation between serum zeaxanthin and MPOD levels could be explained by each patient having varying levels of expression for carotenoid-specific binding proteins in the macula. 30, 41, 45 No dietary restrictions were placed on the patients, which could also be responsible for variations in serum zeaxanthin levels. Finally, compliance appeared high based on pill counts; however, whether the patients actually ingested the zeaxanthin pills is unknown, which could be another explanation as to the lack of correlation between serum zeaxanthin levels and MPOD. Previous reports have described retinal crystalline formation from various medications or exogenous substances, such as nitrofurantoin, tamoxifen, methoxyflurane, ethylene glycol, oxalic acid, and talc from intravenous drugs. [48] [49] [50] Canthaxanthin, one of the 600 naturally occurring carotenoids, when ingested in sufficient amounts can also result in the formation of retinal crystals. 51, 52 We describe the first case of crystalline retinopathy from oral zeaxanthin supplementation. These crystals were localized in the inner retina as determined by OCT, unlike those observed at the vitreoretinal interface seen in MacTel. Visual acuity was not affected by the crystals, and the patient did not experience any scotomas from them. Unlike canthaxanthin crystals, these crystals were rapidly reversible because they dissolved within months of cessation of zeaxanthin supplementation. These crystals were very similar to our recently described crystalline maculopathy associated with high-dose lutein supplementation except the lutein crystals were located in the fovea. 53 Our study showed that patients with Class III MacTel on zeaxanthin supplementation increased MPOD in areas with preserved MP at baseline, and there was no improvement in functional vision as measured by visual acuity or CS. Rather, these values appeared to worsen slightly over the course of the study, consistent with the natural history of the disease.
The limitations of our study include the lack of a placebo control and a small sample size, which makes it difficult to determine statistically significant outcomes, especially with regard to whether zeaxanthin supplementation could improve functional vision, halt progression of the disease, or delay remodeling of MP.
Zeimer et al 8 determined in a 5-year follow-up study that in patients with MacTel without any carotenoid supplementation, there was a small increase in the MPOD at the 4.53°to 6.21°eccentricity. Based on this study, the level of MPOD accumulation at the 5°to 7°e ccentricity determined appears to be larger than would be expected for unsupplemented MacTel patients; however, a larger study with appropriate control subjects is necessary to determine this with statistical significance. Another shortcoming was the use of single-wavelength AFI instead of dual-wavelength AFI because digitally subtracting an autofluorescence image taken at a wavelength (550 nm) with minimal MP absorption improves image quality and reliability of assessing distribution of MP, 54 but unfortunately, this feature was not available on the Spectralis in the United States at the time of this study. Future studies should look into the effect of mesozeaxanthin supplementation on MP distribution in MacTel patients, as one study has shown that carotenoid formulations, including meso-zeaxanthin, showed an increase in MPOD at all eccentricities and visual performance in normal subjects compared with those on carotenoid formulations without meso-zeaxanthin. 55 Other studies have shown a statistically significant augmentation of the MP spatial profile in patients with age-related macular degeneration on a carotenoid formulation containing meso-zeaxanthin versus one without it. 56, 57 Future studies comprising larger intervention groups will be necessary to answer these questions with clinical significance.
Although we showed no beneficial effect of zeaxanthin supplementation, many of the subjects believed that they were seeing better, and the majority of our subjects have continued taking zeaxanthin supplements on their own after the completing the study. Until further studies are performed, we conclude that zeaxanthin supplementation in MacTel patients at 10 mg per day is generally safe and might increase MPOD in the ring surrounding the fovea, but it does not increase foveal pigment density and results in no objective visual benefit.
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